Trial · NCT07294469
Menthol for Improving Movement and Sleep in Parkinson's Disease Patients
NCT07294469, Phase 2, Not yet recruiting, Taipei Medical University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Menthol for Improving Movement and Sleep in Parkinson's Disease Patients. Trials, record NCT07294469. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07294469
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Menthol for Improving Movement and Sleep in Parkinson's Disease Patients
- NCT number
- NCT07294469
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Taipei Medical University Hospital
- Conditions
- Parkinson's Disease
- Interventions
- Menthol gloves and socks, Placebo gloves and socks
- First posted
- 2025-12-19
- Last updated
- 2026-01-08
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Unified Parkinson's Disease Rating Scale (UPDRS) I,II,III | Evaluations will be conducted at the time of randomization and will serve as baseline data. | The UPDRS is a clinical tool to assess the severity of Parkinson's disease. It consists of: Part I: Mentation, Behavior, and Mood (cognitive and psychiatric symptoms); Part II: Activities of Daily Living (self-reported motor activities); Part III: Motor Examination (clinician-assessed motor symptoms); The combined score of Parts I, II, and III reflects overall disease severity. |
| Primary | Unified Parkinson's Disease Rating Scale (UPDRS) I,II,III | Evaluations will be conducted at the fourth week after the start of the intervention. | The UPDRS is a clinical tool to assess the severity of Parkinson's disease. It consists of: Part I: Mentation, Behavior, and Mood (cognitive and psychiatric symptoms); Part II: Activities of Daily Living (self-reported motor activities); Part III: Motor Examination (clinician-assessed motor symptoms); The combined score of Parts I, II, and III reflects overall disease severity. |
| Primary | Unified Parkinson's Disease Rating Scale (UPDRS) I,II,III | Evaluations will be conducted at the fourth week after the end of the intervention, i.e. the eighth week after start of intervention. | The UPDRS is a clinical tool to assess the severity of Parkinson's disease. It consists of: Part I: Mentation, Behavior, and Mood (cognitive and psychiatric symptoms); Part II: Activities of Daily Living (self-reported motor activities); Part III: Motor Examination (clinician-assessed motor symptoms); The combined score of Parts I, II, and III reflects overall disease severity. |
| Primary | Pittsburgh Sleep Quality Index (PSQI) | Evaluations will be conducted at the time of randomization and will serve as baseline data. | The PSQI is a self-report questionnaire assessing sleep quality and disturbances over the past month. It consists of 19 items across 7 domains: sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. |
| Primary | Pittsburgh Sleep Quality Index (PSQI) | Evaluations will be conducted at the fourth week after the start of the intervention. | The PSQI is a self-report questionnaire assessing sleep quality and disturbances over the past month. It consists of 19 items across 7 domains: sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. |
| Primary | Pittsburgh Sleep Quality Index (PSQI) | Evaluations will be conducted at the fourth week after the end of the intervention, i.e. the eighth week after start of intervention. | The PSQI is a self-report questionnaire assessing sleep quality and disturbances over the past month. It consists of 19 items across 7 domains: sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. |
| Secondary | Parkinson's Disease Sleep Scale-2 (PDSS-2) | Evaluations will be conducted at the time of randomization and will serve as baseline data. | The PDSS-2 is a self-reported tool designed to assess sleep disturbances specifically in individuals with Parkinson's disease. It includes 15 items covering various sleep-related issues such as sleep onset, duration, nocturnal motor symptoms, and daytime sleepiness. |
| Secondary | Parkinson's Disease Sleep Scale-2 (PDSS-2) | Evaluations will be conducted at the fourth week after the start of the intervention. | The PDSS-2 is a self-reported tool designed to assess sleep disturbances specifically in individuals with Parkinson's disease. It includes 15 items covering various sleep-related issues such as sleep onset, duration, nocturnal motor symptoms, and daytime sleepiness. |
| Secondary | Parkinson's Disease Sleep Scale-2 (PDSS-2) | Evaluations will be conducted at the fourth week after the end of the intervention, i.e. the eighth week after start of intervention. | The PDSS-2 is a self-reported tool designed to assess sleep disturbances specifically in individuals with Parkinson's disease. It includes 15 items covering various sleep-related issues such as sleep onset, duration, nocturnal motor symptoms, and daytime sleepiness. |
| Secondary | Parkinson's Disease Questionnaire (PDQ-39) | Evaluations will be conducted at the time of randomization and will serve as baseline data. | The PDQ-39 is a 39-item self-report questionnaire designed to assess health-related quality of life in people with Parkinson's disease. It covers 8 domains: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and sleep. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 35897101 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07294469
GET https://conductscience.org/api/trials/v1/NCT07294469/registered